Leonid Timashev
Stock Analyst at RBC Capital
(3.97)
# 721
Out of 5,022 analysts
108
Total ratings
55.1%
Success rate
10.37%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Upgrades: Outperform | $42 → $44 | $31.94 | +37.76% | 4 | Sep 26, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $36 → $38 | $27.07 | +40.38% | 2 | Sep 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $145 → $151 | $133.81 | +12.85% | 1 | Aug 28, 2025 | |
| XNCR Xencor | Maintains: Outperform | $32 → $15 | $12.43 | +20.68% | 1 | Aug 21, 2025 | |
| INSM Insmed | Maintains: Outperform | $120 → $138 | $161.38 | -14.49% | 5 | Aug 13, 2025 | |
| LEGN Legend Biotech | Maintains: Outperform | $75 → $77 | $33.23 | +131.72% | 13 | Aug 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $12 → $13 | $9.00 | +44.44% | 2 | Aug 8, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $6 → $7 | $3.55 | +97.18% | 2 | Aug 8, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $48 → $49 | $14.70 | +233.33% | 14 | Aug 8, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Outperform | $38 → $39 | $37.86 | +3.01% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $349 → $364 | $320.94 | +13.42% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $184 → $189 | $123.52 | +53.01% | 13 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $50 → $45 | $39.51 | +13.90% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $25 | $7.89 | +216.86% | 1 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $53 | $42.85 | +23.69% | 1 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 → $17 | $10.54 | +61.29% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $4.11 | +21.65% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $4.84 | +230.58% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $54 → $21 | $16.66 | +26.05% | 12 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $80 | $61.03 | +31.08% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.23 | +147.68% | 6 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.40 | +114.29% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $85.96 | -18.57% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $6.84 | +163.16% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $6.62 | -39.58% | 8 | Aug 6, 2024 |
Alkermes
Sep 26, 2025
Upgrades: Outperform
Price Target: $42 → $44
Current: $31.94
Upside: +37.76%
IDEAYA Biosciences
Sep 9, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $27.07
Upside: +40.38%
Jazz Pharmaceuticals
Aug 28, 2025
Maintains: Outperform
Price Target: $145 → $151
Current: $133.81
Upside: +12.85%
Xencor
Aug 21, 2025
Maintains: Outperform
Price Target: $32 → $15
Current: $12.43
Upside: +20.68%
Insmed
Aug 13, 2025
Maintains: Outperform
Price Target: $120 → $138
Current: $161.38
Upside: -14.49%
Legend Biotech
Aug 12, 2025
Maintains: Outperform
Price Target: $75 → $77
Current: $33.23
Upside: +131.72%
Verastem
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $9.00
Upside: +44.44%
Nuvation Bio
Aug 8, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $3.55
Upside: +97.18%
Edgewise Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $48 → $49
Current: $14.70
Upside: +233.33%
NewAmsterdam Pharma Company
Aug 7, 2025
Maintains: Outperform
Price Target: $38 → $39
Current: $37.86
Upside: +3.01%
Aug 7, 2025
Maintains: Outperform
Price Target: $349 → $364
Current: $320.94
Upside: +13.42%
Aug 5, 2025
Maintains: Outperform
Price Target: $184 → $189
Current: $123.52
Upside: +53.01%
Jul 29, 2025
Maintains: Sector Perform
Price Target: $50 → $45
Current: $39.51
Upside: +13.90%
Jul 17, 2025
Maintains: Outperform
Price Target: $32 → $25
Current: $7.89
Upside: +216.86%
Jul 16, 2025
Maintains: Outperform
Price Target: $68 → $53
Current: $42.85
Upside: +23.69%
Jun 20, 2025
Reiterates: Outperform
Price Target: $13 → $17
Current: $10.54
Upside: +61.29%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $4.11
Upside: +21.65%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $4.84
Upside: +230.58%
May 19, 2025
Downgrades: Sector Perform
Price Target: $54 → $21
Current: $16.66
Upside: +26.05%
May 7, 2025
Maintains: Outperform
Price Target: $82 → $80
Current: $61.03
Upside: +31.08%
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.23
Upside: +147.68%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.40
Upside: +114.29%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $85.96
Upside: -18.57%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $6.84
Upside: +163.16%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $6.62
Upside: -39.58%